ABBV-744 CANCER TREATMENT CLINICAL TRIALS - AN OVERVIEW

In Segment C, participants will get ABBV-744 and oral navitoclax. In Phase D, contributors will obtain ABBV-744 and ruxolitinib. Members will acquire treatment till sickness progression or even the members are unable to tolerate the study drugs.- "Our study uncovered the vital position on the KLF16/MYC regulatory axis in modulating tumor progress a